- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07740694
EEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT
The Relationship Between EEG Microstate Parameters, Neuroinflammatory Biomarkers and Treatment Response in Older Patients With Major Depressive Disorder or Bipolar Disorder Undergoing Electroconvulsive Therapy
Descripción general del estudio
Estado
Condiciones
- Depresión bipolar
- Catatonia
- Episodio depresivo mayor
- Desorden afectivo bipolar
- Depresión Mayor Con Ataques De Pánico
- Depresión mayor con rasgos psicóticos
- Depresión mayor con síntomas de ansiedad comórbida
- Depresión Anhedónica Bipolar
- Depresión mayor moderada
- Depresión mayor severa
- Depresión bipolar fase deprimida
Intervención / Tratamiento
Descripción detallada
Major Depressive Disorder (MDD) and Major Depressive Episodes are leading causes of disability worldwide because of the substantial functional impairment they cause in affected individuals as well as their considerable socioeconomic burden. Late-life depression is associated with physical disability, worsening of coexisting medical illnesses, institutionalization, and increased mortality. The primary goals of treatment are to achieve complete remission, restore psychosocial functioning and quality of life, and prevent relapse and recurrence. All patients diagnosed with depression should receive appropriate psychoeducation, followed by antidepressant pharmacotherapy and/or psychotherapy through a shared decision-making process involving both the clinician and the patient.
Electroconvulsive therapy (ECT) is currently regarded as one of the most effective treatment modalities for Major Depressive Episode. Among elderly patients with severe major depressive episode, with or without psychotic features, particularly those presenting with active suicidal ideation, inadequate response to pharmacotherapy and/or psychotherapy, or intolerance to pharmacological treatment, ECT provides rapid clinical improvement with remission rates approaching 80%, making it one of the most effective biological treatment options currently available. Despite its well-established clinical efficacy, the mechanisms underlying ECT's therapeutic effects remain incompletely elucidated, and several biological, neurochemical, and structural hypotheses have been proposed.
Electroencephalography (EEG) is a non-invasive neurophysiological technique that measures fluctuations in the electrical activity generated by neuronal populations with excellent temporal resolution. Brief periods of stable scalp topographies lasting approximately 80-120 milliseconds are referred to as EEG microstates. These microstates are considered the electrophysiological correlates of transient large-scale functional brain networks. Parameters such as microstate duration, frequency of occurrence, coverage, and transition probability provide valuable information about the brain's functional organization and dynamic stability.
Although EEG-based studies investigating the effects of ECT on neuroplasticity, neurotransmitter systems, hippocampal volume, functional connectivity, and electrophysiological dynamics have attracted increasing attention in recent years, studies specifically focusing on EEG microstate analysis remain limited, especially in the older age population. Existing investigations are generally characterized by relatively small sample sizes, heterogeneity in treatment protocols, and methodological differences that may influence microstate measurements, emphasizing the need for larger and better-controlled studies.
As the search for reliable predictors of treatment response has intensified, increasing evidence suggests that abnormalities in immune regulation contribute to the pathophysiology of both unipolar and bipolar depression, highlighting the immune system as a promising source of biological markers. In particular, accumulating evidence indicates that pro-inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP), as well as anti-inflammatory cytokines such as interleukin-2 (IL-2) and interleukin-10 (IL-10), are involved in the pathophysiology of depression and may influence response to antidepressant treatment and electroconvulsive therapy (8-10). Furthermore, a recent meta-analysis demonstrated significantly higher neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) values in patients with depression compared with healthy controls. However, studies evaluating NLR, PLR, and monocyte-to-lymphocyte ratio (MLR) as predictors of response to ECT remain scarce.
Accordingly, the present study aims to investigate the neurophysiological changes associated with ECT in elderly patients diagnosed with Major Depressive Disorder through resting-state EEG microstate analysis. EEG recordings obtained before and after ECT will be compared to determine whether significant changes occur in microstate parameters, including duration, frequency, coverage, and transition probability. Furthermore, the relationships between changes in EEG microstate parameters and psychometric measures reflecting clinical improvement will be evaluated.
In addition, peripheral blood samples obtained from the same patient cohort will be analyzed to determine complete blood count parameters together with concentrations of interleukin-1 alpha (IL-1α), interleukin-1 beta (IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), soluble glycoprotein-130 (sgp130), soluble interleukin-6 receptor (sIL-6R), C-reactive protein (CRP), and inflammatory indices including NLR, PLR, and MLR. Baseline inflammatory biomarker levels will be evaluated as potential predictors of treatment response, while post-treatment changes will be examined in relation to both clinical outcomes and EEG microstate parameters. By investigating the interactions between neurophysiological and inflammatory biomarkers, this study aims to identify objective predictors of ECT response and contribute to the development of more personalized treatment strategies for late-life depression.
This prospective observational study will be conducted at the Department of Psychiatry, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa. Patients aged 55 years or older who meet the DSM-5 diagnostic criteria for Major Depressive Disorder and Bipolar Disorder Major Depressive Episode, have been clinically indicated for electroconvulsive therapy (ECT), and voluntarily agree to participate in the study will be enrolled after providing written informed consent.
Resting-state EEG recordings will be obtained at three time points: within 1 week before the initiation of ECT, 2 weeks after completion of the ECT course, and 2 months after completion of treatment.
EEG recordings will be acquired using a computerized 19-channel EEG system equipped with Ag-AgCl disc electrodes positioned according to the International 10-20 System. The average of the A1 and A2 earlobe electrodes will serve as the reference. Signals will be sampled at 512 Hz with a high-pass filter of 0.30 Hz, a low-pass filter of 70 Hz, and an additional 50-Hz notch filter.
Each recording session will last 10 minutes under resting-state conditions, consisting of 5 minutes with eyes open followed by 5 minutes with eyes closed. Participants will be instructed to remain awake, relaxed, motionless, and silent throughout the recording. Raw EEG data will undergo standard preprocessing procedures, including artifact rejection, band-pass filtering, and re-referencing before subsequent analyses.
EEG microstate analysis will be performed using MICROSTATELAB v2.1, an EEGLAB extension implemented in MATLAB. Four canonical EEG microstate classes (A, B, C, and D) will be identified for each participant.
The following microstate parameters will be calculated:
Duration: the mean duration (milliseconds) during which an individual microstate remains stable after onset, reflecting the temporal stability of the underlying neural network.
Frequency (Occurrence): the average number of occurrences of each microstate per second (Hz), representing the activation tendency of the corresponding functional network.
Coverage: the percentage of the total recording time occupied by each microstate, reflecting its relative contribution to overall brain activity.
Transition Probability (TP): the probability of transitions between different microstate classes. For example, the transition probability from microstate A to microstate B is calculated as the proportion of A-to-B transitions relative to all transitions originating from microstate A. This parameter provides information regarding the sequential dynamics of large-scale brain network activation.
Clinical Assessments
Before initiation of ECT, all patients will undergo a comprehensive clinical evaluation including a sociodemographic data form, ECT follow-up form, Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Montgomery-Åsberg Depression Rating Scale (MADRS), Beck Scale for Suicide Ideation (BSSI), Clinical Global Impression Scale (CGI), Center for Epidemiologic Studies Depression Scale (CES-D), Cumulative Illness Rating Scale-Geriatric (CIRS-G), Maudsley Staging Scale (MSS), and Mini-Mental State Examination (MMSE).
Rating scales will be administered at each EEG assessment time point, whereas clinical follow-up forms will be completed throughout the treatment period. Treatment response will be defined as a reduction of at least 50% in the baseline HAM-D-17 score, while remission will be defined as a HAM-D-17 score below 7.
Peripheral venous blood samples will be collected from all patients at three time points: before the first ECT session (between 07:30 and 09:30 a.m. under fasting conditions), two weeks after completion of the ECT course, and eight weeks after treatment completion.
Blood samples will be collected into 10-mL K2EDTA tubes (BD, UK), centrifuged at 4,000 rpm for 10 minutes, and plasma aliquots will be stored at -80°C until biochemical analyses are performed.
Complete blood count parameters together with inflammatory biomarkers including pro-inflammatory and anti-inflammatory cytokines, C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) will be analyzed.
Age-matched healthy volunteers will also be recruited. Healthy controls will complete a sociodemographic questionnaire, MMSE, BDI, and BAI. A single resting-state EEG recording consisting of 5 minutes with eyes open and 5 minutes with eyes closed will be obtained. Peripheral blood samples will also be collected for inflammatory biomarker analyses using the same laboratory procedures as those applied to the patient group.
Sample size estimation was performed using G*Power version 3.1.9 (Faul et al., 2009). Based on an effect size of 0.70 and a statistical power (1-β) of 0.85, the required sample size was calculated to be 31 patients and 31 healthy controls. The power analysis was based on clinical treatment response as the primary outcome measure.
The study population will consist of older-age patients diagnosed with Major Depressive Episode who are scheduled to receive electroconvulsive therapy at the Department of Psychiatry, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, and who voluntarily agree to participate in the study.
EEG preprocessing and microstate analyses will be performed using EEGLAB implemented in MATLAB. Statistical analyses will be conducted using IBM SPSS Statistics version 27.
Continuous variables will be presented as mean ± standard deviation or median (interquartile range), depending on data distribution, whereas categorical variables will be summarized as frequencies and percentages.
Normality of continuous variables will be assessed using the Shapiro-Wilk test.
For comparisons of repeated measurements obtained before ECT, two weeks after ECT, and two months after ECT, repeated-measures analysis of variance (repeated-measures ANOVA) will be used for normally distributed variables. When the assumptions for parametric testing are not met, the Friedman test will be performed. Pairwise comparisons will be adjusted using appropriate post hoc correction methods.
Comparisons between patients and healthy controls will be performed using the independent-samples Student's t-test or the Mann-Whitney U test, depending on data distribution.
Categorical variables will be analyzed using the Chi-square test or Fisher's exact test, as appropriate.
Correlations between continuous variables, including EEG microstate parameters, inflammatory biomarkers, and psychometric scale scores, will be evaluated using Pearson's or Spearman's correlation coefficients, depending on the data distribution.
To identify independent predictors of treatment response, multivariable logistic regression analysis will be performed. Statistical significance will be defined as a two-sided p-value < 0.05.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Zeynep Dagoglu Sarac, Dr
- Número de teléfono: +905365942469
- Correo electrónico: zod395@gmail.com
Ubicaciones de estudio
-
-
Bakırköy
-
Istanbul, Bakırköy, Turquía (Türkiye)
- Reclutamiento
- İstanbul University- Cerrahpasa, Cerrahpasa Medicine Faculty, Psychiatry Department
-
Contacto:
- Ahmet Torun, Dr
- Número de teléfono: +905526125942
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
Patient Group
- Age ≥55 years.
- Diagnosis of Major Depressive Disorder or Bipolar Disorder, current major depressive episode, according to DSM-5 criteria.
- Clinical indication for electroconvulsive therapy (ECT).
- Ability to provide written informed consent.
- Willingness to participate in the study.
Healthy Control Group:
- Age ≥55 years.
- No current psychiatric disorder.
- No known neurological disorder.
- Good general physical health.
- No current use of medications known to affect EEG activity or inflammatory biomarkers significantly.
- Ability to provide written informed consent.
- Willingness to participate in the study.
Exclusion Criteria:
- Primary neurological disorders (e.g., dementia or traumatic brain injury).
- Schizophrenia or other psychotic disorders.
- Intracranial space-occupying lesions.
- Increased intracranial pressure.
- Myocardial infarction within the previous 3 months.
- Cerebrovascular disease within the previous month.
- Unstable cerebral aneurysm.
- Pheochromocytoma.
- Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within the previous month.
- Cognitive impairment severe enough to prevent adequate cooperation during EEG recording.
- Current alcohol or substance use disorder.
- Active infectious disease.
- Uncontrolled autoimmune or chronic inflammatory disorders. Participants with stable disease who had received the same maintenance treatment within the previous 3 months were eligible for inclusion.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Patients with Major Depressive Disorder who was suggested ECT clinically
People over 55 years of age who were diagnosed with Major Depressive Episode, whose diagnosis is either Major Depression or Bipolar Depression
|
ECT will be administered using the Thymatron System IV Integrated ECT Device under general anesthesia according to standard clinical protocols.
Treatments will be delivered using bilateral electrode placement (or right unilateral if side effects are observed) with brief-pulse squarewave stimulation.
The duration of treatment, number of sessions, and stimulation parameters will be determined according to each patient's clinical condition.
|
|
Healthy Control
The healthy control group will consist of age- and sex-matched volunteers who are 55 years of age or older, who do not use any medication that may significantly influence EEG activity or inflammatory biomarkers, and who do not have a current neurological or psychiatric disorder.
Healthy controls will also provide written informed consent before participation.
EEG recordings will be obtained once and will serve as reference data for normal brain activity.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Clinical Response and Remission Assessed by the Montgomery-Åsberg Depression Rating Scale
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Before ECT initiation and 2 and 8 weeks after the cessation of ECT sessions, depressive symptom severity will be assessed using the Montgomery-Åsberg Depression Rating Scale.
Montgomery-Åsberg Depression Rating Scale total score ranges from 0 to 60, with higher scores indicating greater severity of depressive symptoms.
Change in total score from baseline will be assessed following electroconvulsive therapy (ECT).Clinical response will be defined as a ≥50% reduction in MADRS total score from baseline.
Remission will be defined as a MADRS total score ≤7.
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Clinical Response Assessed by Hamilton Depression Rating Scale
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Before ECT initiation and 2 and 8 weeks after the cessation of ECT sessions, depressive symptom severity will be assessed using the Hamilton Depression Rating Scale.
The total score of scale ranges from 0 to 52, with higher scores indicating greater severity of depressive symptoms.
Change in Hamilton Depression Rating Scale total score from baseline will be assessed following electroconvulsive therapy (ECT).Clinical response will be defined as a ≥50% reduction in total score from baseline.
Remission will be defined as a total score ≤7.
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
EEG Microstate Duration
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Participants will be instructed to remain relaxed, quiet, and motionless during EEG recording.
EEG acquisition will consist of 5 minutes with eyes open followed by 5 minutes with eyes closed.
Raw EEG data will undergo preprocessing, including artifact removal, band-pass filtering, and re-referencing.
Microstate analysis will be performed using MICROSTATELAB v2.1, an EEGLAB extension.
Four canonical microstate classes (A, B, C, and D) will be identified.
For each microstate class, duration will be calculated as the mean time for which the microstate remains stable following its onset and will be reported in milliseconds (ms).
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
EEG Microstate Occurrence
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Participants will be instructed to remain relaxed, quiet, and motionless during EEG recording.
EEG acquisition will consist of 5 minutes with eyes open followed by 5 minutes with eyes closed.
Raw EEG data will undergo preprocessing, including artifact removal, band-pass filtering, and re-referencing.
Microstate analysis will be performed using MICROSTATELAB v2.1, an EEGLAB extension.
Four canonical microstate classes (A, B, C, and D) will be identified.
For each microstate class, occurrence will be calculated as the mean number of times the microstate occurs per second and will be reported in Hertz (Hz).
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
EEG Microstate Coverage
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Participants will be instructed to remain relaxed, quiet, and motionless during EEG recording.
EEG acquisition will consist of 5 minutes with eyes open followed by 5 minutes with eyes closed.
Raw EEG data will undergo preprocessing, including artifact removal, band-pass filtering, and re-referencing.
Microstate analysis will be performed using MICROSTATELAB v2.1, an EEGLAB extension.
Four canonical microstate classes (A, B, C, and D) will be identified.
For each microstate class, coverage will be calculated as the percentage of the total EEG recording time occupied by that microstate class and will be reported as a percentage (%).
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
EEG Microstate Transition Probability
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Participants will be instructed to remain relaxed, quiet, and motionless during EEG recording.
EEG acquisition will consist of 5 minutes with eyes open followed by 5 minutes with eyes closed.
Raw EEG data will undergo preprocessing, including artifact removal, band-pass filtering, and re-referencing.
Microstate analysis will be performed using MICROSTATELAB v2.1, an EEGLAB extension.
Four canonical microstate classes (A, B, C, and D) will be identified.
For each pair of microstate classes, transition probability will be calculated as the proportion of transitions from a given microstate class to a specific subsequent microstate class relative to all transitions originating from that microstate class.
Transition probability will be reported as a proportion ranging from 0 to 1.
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Correlation between baseline neuroinflammatory biomarkers and treatment response
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Correlation coefficients between baseline concentrations of neuroinflammatory biomarkers and change in Hamilton Depression Rating Scale scores following ECT will be calculated.
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Clinical Response Assessed by Center for Epidemiologic Studies Depression Scale
Periodo de tiempo: These assessments will be repeated within 1 week before ECT start and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Depressive symptoms will be assessed using the Center for Epidemiologic Studies Depression Scale before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions.
The scale consists of 20 items, with a total score ranging from 0 to 60; higher scores indicate greater severity of depressive symptoms.
Changes in the total scores from baseline will be evaluated following ECT.
|
These assessments will be repeated within 1 week before ECT start and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Correlation between changes in neuroinflammatory biomarkers and EEG microstate parameters
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Correlation coefficients between changes in neuroinflammatory biomarker concentrations and changes in EEG microstate parameters (duration, occurrence, coverage, and transition probabilities) following ECT will be calculated.
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Inflammatory indices derived from complete blood count
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Neutrophil-to-Lymphocyte Ratio (NLR) will be calculated from complete blood count parameters and expressed as a ratio.
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Inflammatory indices derived from complete blood count
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Platelet-to-Lymphocyte Ratio (PLR) will be calculated from complete blood count parameters and expressed as a ratio.
|
These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Inflammatory indices derived from complete blood count
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Monocyte-to-Lymphocyte Ratio (MLR) will be calculated from complete blood count parameters and expressed as a ratio.
|
These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Correlation between baseline neuroinflammatory biomarkers and treatment response
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Correlation coefficients between baseline concentrations of neuroinflammatory biomarkers and change in Montgomery-Asberg Depression Rating Scale scores following ECT will be calculated.
|
These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Clinical Response Assessed by Beck Depression Inventory
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Depressive symptoms will be assessed using the Beck Depression Inventory before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions.
The Beck Depression Inventory consists of 21 items, with a total score ranging from 0 to 63; higher scores indicate greater severity of depressive symptoms.
A ≥50% reduction in the total score from baseline will be used to define treatment response, and a total score ≤9 will be used to define remission.
|
These assessments will be repeated within 1 week before ECT starts, and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Clinical Response Assessed by Beck Anxiety Scale
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Anxiety symptoms will be assessed using the Beck Anxiety Inventory before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions.
The Beck Anxiety Inventory consists of 21 items, with a total score ranging from 0 to 63; higher scores indicate greater severity of anxiety symptoms.
A ≥50% reduction in the total score from baseline will be used to define treatment response, and a total score ≤10 will be used to define remission.
|
These assessments will be repeated within 1 week before ECT starts and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Clinical Response Assessed by Hamilton Anxiety Scale
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Anxiety symptoms will be assessed using the Hamilton Anxiety Rating Scale before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions.
The Hamilton Anxiety Rating Scale consists of 14 items, with a total score ranging from 0 to 56; higher scores indicate greater severity of anxiety symptoms.
A ≥50% reduction in the total score from baseline will be used to define treatment response, and a total score ≤7 will be used to define remission.
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Clinical Response Assessed by Beck Scale for Suicidal Ideation
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Suicidal ideation will be assessed using the Beck Scale for Suicide Ideation before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions.
The Beck Scale for Suicide Ideation consists of 19 scored items, with a total score ranging from 0 to 38; higher scores indicate greater severity of suicidal ideation.
A ≥50% reduction in the Beck Scale for Suicide Ideation total score from baseline will be used to define treatment response, and a total score ≤6 will be used to define remission.
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Clinical Response Assessed by Clinical Global Impression- Severity
Periodo de tiempo: These assessments will be repeated within 1 week before ECT start and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Overall illness severity will be assessed using the Clinical Global Impression-Severity scale before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions.
The scale is a 7-point clinician-rated scale ranging from 3 to 18, with higher scores indicating greater overall illness severity.
Changes in CGI-S the scale scores from baseline will be evaluated following ECT.
|
These assessments will be repeated within 1 week before ECT start and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Concentration of peripheral neuroinflammatory biomarkers
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Concentrations of soluble glycoprotein 130 (sgp130) and soluble interleukin-6 receptor (sIL-6R) will be measured from peripheral blood samples using ELISA assays.
(ng/ml).
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Concentration of peripheral neuroinflammatory biomarkers
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Concentrations of IL-1α, IL-1β, IL-2, IL-6, IL-8, IL-10, TNF-α, interferon gamma-induced protein-10 (IP-10), will be measured from peripheral blood samples using ELISA assays ( pg/mL).
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
|
Concentration of peripheral neuroinflammatory biomarkers
Periodo de tiempo: These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Concentrations of C-reactive protein (CRP) will be measured from peripheral blood samples using ELISA assays ( mg/L).
|
These assessments will be repeated within 1 week before ECT starts, and at 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Clinical Cognitive Assessment
Periodo de tiempo: These assessments will be repeated within 1 week before ECT start and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Cognitive function will be assessed using the Mini-Mental State Examination before ECT initiation and at 2 and 8 weeks after the cessation of ECT sessions.
The scale is a clinician-administered cognitive assessment with a total score ranging from 0 to 30, with higher scores indicating better cognitive function.
Changes in the total scores from baseline will be evaluated following ECT.
|
These assessments will be repeated within 1 week before ECT start and 14+6 days and 8 weeks + 6 days after ECT cessation.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Alperen Kılıç, Associate Professor, Istanbul University - Cerrahpasa
- Director de estudio: Burc Cagrı Poyraz, Professor, Istanbul University - Cerrahpasa
Publicaciones y enlaces útiles
Publicaciones Generales
- Brodbeck V, Kuhn A, von Wegner F, Morzelewski A, Tagliazucchi E, Borisov S, Michel CM, Laufs H. EEG microstates of wakefulness and NREM sleep. Neuroimage. 2012 Sep;62(3):2129-39. doi: 10.1016/j.neuroimage.2012.05.060. Epub 2012 May 30.
- White J, Kivimaki M, Jokela M, Batty GD. Association of inflammation with specific symptoms of depression in a general population of older people: The English Longitudinal Study of Ageing. Brain Behav Immun. 2017 Mar;61:27-30. doi: 10.1016/j.bbi.2016.08.012. Epub 2016 Aug 22.
- Carlier A, Berkhof JG, Rozing M, Bouckaert F, Sienaert P, Eikelenboom P, Veerhuis R, Vandenbulcke M, Berkhof J, Stek ML, Rhebergen D, Dols A, Exel EV. Inflammation and remission in older patients with depression treated with electroconvulsive therapy; findings from the MODECT study✰. J Affect Disord. 2019 Sep 1;256:509-516. doi: 10.1016/j.jad.2019.06.040. Epub 2019 Jul 1.
- Sackeim HA, Prudic J, Nobler MS, Fitzsimons L, Lisanby SH, Payne N, Berman RM, Brakemeier EL, Perera T, Devanand DP. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimul. 2008 Apr;1(2):71-83. doi: 10.1016/j.brs.2008.03.001.
- Cheng Y, Wang Y, Wang X, Jiang Z, Zhu L, Fang S. Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Monocyte-to-Lymphocyte Ratio in Depression: An Updated Systematic Review and Meta-Analysis. Front Psychiatry. 2022 Jun 15;13:893097. doi: 10.3389/fpsyt.2022.893097. eCollection 2022.
- Kruse JL, Olmstead R, Hellemann G, Wade B, Jiang J, Vasavada MM, Brooks Iii JO, Congdon E, Espinoza R, Narr KL, Irwin MR. Inflammation and depression treatment response to electroconvulsive therapy: Sex-specific role of interleukin-8. Brain Behav Immun. 2020 Oct;89:59-66. doi: 10.1016/j.bbi.2020.05.069. Epub 2020 May 29.
- Ryan KM, McLoughlin DM. Peripheral blood inflammatory markers in depression: Response to electroconvulsive therapy and relationship with cognitive performance. Psychiatry Res. 2022 Sep;315:114725. doi: 10.1016/j.psychres.2022.114725. Epub 2022 Jul 16.
- Liu JJ, Wei YB, Strawbridge R, Bao Y, Chang S, Shi L, Que J, Gadad BS, Trivedi MH, Kelsoe JR, Lu L. Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. Mol Psychiatry. 2020 Feb;25(2):339-350. doi: 10.1038/s41380-019-0474-5. Epub 2019 Aug 19.
- Atluri S, Wong W, Moreno S, Blumberger DM, Daskalakis ZJ, Farzan F. Selective modulation of brain network dynamics by seizure therapy in treatment-resistant depression. Neuroimage Clin. 2018;20:1176-1190. doi: 10.1016/j.nicl.2018.10.015. Epub 2018 Oct 17.
- Vass A, Farkas K, Lanyi O, Koi T, Csukly G, Rethelyi JM, Baradits M. Current Status of Electroencephalography Microstate in Psychiatric Disorders: A Systematic Review and Meta-Analysis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2025 Oct;10(10):1015-1024. doi: 10.1016/j.bpsc.2025.04.001. Epub 2025 Apr 11.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos bipolares y relacionados
- Manifestaciones neurológicas
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Síntomas de comportamiento
- Manifestaciones neuroconductuales
- Trastornos del estado de ánimo
- Desorden depresivo
- Condiciones Patológicas, Signos y Síntomas
- Comportamiento
- Signos y síntomas
- Trastorno bipolar
- Trastorno Depresivo Mayor
- Trastorno depresivo, resistente al tratamiento
- Catatonia
Otros números de identificación del estudio
- IstanbulUniversityC
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
- CÓDIGO_ANALÍTICO
- RSC
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .